Your browser doesn't support javascript.
loading
Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size.
Tully, Karl H; Moschini, Marco; von Rundstedt, Friedrich-Carl E; Aziz, Atiqullah; Kluth, Luis A; Necchi, Andrea; Rink, Michael; Hendricksen, Kees; Sargos, Paul; Vetterlein, Malte W; Seiler, Roland; Poyet, Cedric; Krajewski, Wojciech; Fajkovic, Harun; Shariat, Shahrokh F; Xylinas, Evanguelos; Roghmann, Florian.
Afiliação
  • Tully KH; Department of Urology, Ruhr-University Bochum, Marien Hospital, Herne, Germany.
  • Moschini M; Department of Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • von Rundstedt FE; Department of Urology, Jena University Hospital, Friedrich-Schiller- University, Jena, Germany.
  • Aziz A; Department of Urology, München Klinik Bogenhausen, Munich, Germany.
  • Kluth LA; Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany.
  • Necchi A; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Itlay.
  • Rink M; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Hendricksen K; Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Sargos P; Division of Radiation Oncology, McGill University, Montreal, QC, Canada.
  • Vetterlein MW; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Seiler R; Department of Urology, University of Bern, Bern, Switzerland.
  • Poyet C; Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
  • Krajewski W; Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland.
  • Fajkovic H; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Shariat SF; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwest, Dallas, TX; Department of Urology, Second Faculty of Medicine, Charles Universi
  • Xylinas E; Department of Urology, Bichat-Claude Bernard Hospital, Assistance-Publique Hôpitaux de Paris, Paris Descartes University, Paris, France.
  • Roghmann F; Department of Urology, Ruhr-University Bochum, Marien Hospital, Herne, Germany. Electronic address: f.roghmann@gmail.com.
Urol Oncol ; 38(11): 851.e19-851.e25, 2020 11.
Article em En | MEDLINE | ID: mdl-32739227
PURPOSE: To examine survival rates and to calculate the risk of disease recurrence, progression, overall, and cancer-specific mortality in patients diagnosed with high-risk NMIBC using a multi-institutional dataset to evaluate differences between the guidelines of the European Association of Urology and the guidelines of the National Comprehensive Cancer Network (NCCN) with regard to tumor size in risk stratification. METHODS AND MATERIAL: In total 1,116 individuals diagnosed with high-risk NMIBC between 2001 and 2013 were included in the analysis. Patients were stratified to NCCN guideline recommendations (high-grade T1, high-grade Ta ≤ 3 cm, and high-grade Ta > 3 cm). Recurrence and progression rates were calculated. Kaplan-Meier curves were fitted to examine differences in recurrence-free (RFS) and progression-free survival (PFS). Multivariable Cox proportional hazards regression models were employed to calculate differences in the RFS, PFS, overall, and cancer-specific survival (CSS). RESULTS: The majority of patients were diagnosed with high-grade T1 disease (N = 576, 51.6%), while 34.2% and 14.2% of patients were diagnosed with high-grade Ta ≤ 3 cm and Ta > 3 cm NMIBC, respectively. The 1- and 5-year RFS (1-year: 80.5% vs. 64.9%; 5-year: 58.6% vs. 48.3%, P = 0.048) and PFS (1-year: 99.1% vs. 98.6%; 5-year: 97.7% vs. 92.4%, P = 0.054) rates were higher in patients with Ta ≤ 3 cm. Patients diagnosed with high-grade Ta > 3 cm experienced unfavorable progression-free, and cancer-specific survival compared to high-grade Ta ≤ 3 cm, respectively (PFS: 2.41, 95% confidence interval [CI] 1.05-5.56, P = 0.038; CSS: hazard ratios [HR] 2.22, 95% CI 1.02-4.89, P = 0.048). CONCLUSION: Patients diagnosed with high-grade Ta NMIBC ≤3 cm demonstrated a favorable progression-free, and cancer-specific survival compared to patients diagnosed with high-grade Ta > 3 cm and high-grade T1 NMIBC.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Mortalidade / Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Urol Oncol Assunto da revista: NEOPLASIAS / UROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Temas: Mortalidade / Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Urol Oncol Assunto da revista: NEOPLASIAS / UROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha